Matsui T, et al. - The aim of this study was to explore the association between aging and ISR using the food and drug administration adverse event reporting System (FAERS) database. They observed that crude reporting odds ratios (RORs) for etanercept (ETN) + methotrexate (MTX) combination therapy and adalimumab (ADA) + MTX combination therapy were lower than those for the respective monotherapies.